Alejandro Sanz

Dr. Alejandro Sanz

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2024 in Cells
Verified
Journal Article
Open access
PDF file
GGGonzalo García-Aguilera
Gonzalo García-Aguilera
ACAna Castillo-Robleda
Ana Castillo-Robleda
ASAlejandro Sanz
Alejandro Sanz
MRManuel Ramírez
Manuel Ramírez
The ability of flow cytometry to identify and quantify the presence of cell populations defined by their expression profile of specific markers has made this technique a powerful and routinary tool in clinical diagnostic practice. Specifically in the field of hematological malignancies, flow cytometry allows the identification of the correct type and lineage of each patient’s disease and also sensitively quantifies the presence of the disease at precise moments during treatment, that is, levels of measurable residual disease (MRD). The quantification of MRD by flow cytometry has allowed the adaptation of tailored therapies to patients, contributing to the improvement of the results of the different protocols in recent decades. In this context, our objective in the present work was to evaluate the potential impact that spectral flow cytometry can provide compared to conventional cytometry, which is the one usually used in clinics. We present here a comparative study of both technologies, spectral versus conventional flow cytometry, in primary samples corresponding to the diagnosis and follow-up of children and adolescents with acute lymphoblastic leukemia. Our initial experience demonstrates the feasibility of incorporating spectral flow cytometry into the routine workflow of a reference laboratory.

23 August 2022 in Disease Markers
Verified
Journal Article
Open access
PDF file
TCTamara Castaño-Bonilla
Tamara Castaño-Bonilla
EBEva Barragán
Eva Barragán
CSClaudia Sargas
Claudia Sargas
ASAlejandro Sanz
Alejandro Sanz
LALorenzo Algarra
Lorenzo Algarra
PMPau Montesinos
Pau Montesinos
Gemtuzumab ozogamicin (GO) is a conjugate of a monoclonal antibody and calicheamicin, which has been reapproved for the treatment of acute myeloid leukemia (AML). AML patients with the CD33 rs12459419 CC genotype might benefit from the addition of GO to intensive treatment in contrast to patients with CT/TT genotypes. Nevertheless, contradictory results have been reported. We sought to shed light on the prediction of GO response in AML patients with rs12459419 polymorphism who were treated with GO in the consolidation ( ) or reinduction ( ) phase. The frequency distribution of the rs12459419 polymorphism in the complete cohort of patients was 44.4% ( ), 50% ( ), and 5.6% ( ) for CC, CT, and TT genotypes, respectively. Regarding the patients treated with GO for consolidation, we performed a Kaplan-Meier analysis of overall survival and relapse-free survival according to the rs12459419 polymorphism (CC vs. CT/TT patients) and genetic risk using the European Leukemia Net (ELN) 2010 risk score. We also carried out a Cox regression analysis for the prediction of overall survival, with age and ELN 2010 as covariates. We found no statistical significance in the univariate or multivariate analysis. Additionally, we performed a global Kaplan-Meier analysis for the patients treated with GO for reinduction and did not find significant differences; however, our cohort was too small to draw any conclusion from this analysis. The use of GO in consolidation treatment is included in the approval of the compound; however, evidence regarding its efficacy in this setting is lacking. Rs12459419 polymorphism could help in the selection of patients who might benefit from GO. Regrettably, in our cohort, the rs12459419 polymorphism does not seem to be an adequate tool for the selection of patients who might benefit from the addition of GO in consolidation cycles.

27 April 2024 in Genes
Verified
Journal Article
Open access
PDF file
JIJune Iriondo
June Iriondo
AGAna Gómez
Ana Gómez
JZJosune Zubicaray
Josune Zubicaray
JMJorge García Martínez
Jorge García Martínez
LALorea Abad
Lorea Abad
JSJulián Sevilla
Julián Sevilla
Cytogenetic studies are essential in the diagnosis and follow up of patients with bone marrow failure syndromes (BMFSs), but obtaining good quality results is often challenging due to hypocellularity. Optical Genome Mapping (OGM), a novel technology capable of detecting most types chromosomal structural variants (SVs) at high resolution, is being increasingly used in many settings, including hematologic malignancies. Herein, we compared conventional cytogenetic techniques to OGM in 20 patients with diverse BMFSs. Twenty metaphases for the karyotype were only obtained in three subjects (15%), and no SVs were found in any of the samples. One patient with culture failure showed a gain in chromosome 1q by fluorescence in situ hybridization, which was confirmed by OGM. In contrast, OGM provided good quality results in all subjects, and SVs were detected in 14 of them (70%), mostly corresponding to cryptic submicroscopic alterations not observed by standard techniques. Therefore, OGM emerges as a powerful tool that provides complete and evaluable results in hypocellular BMFSs, reducing multiple tests into a single assay and overcoming some of the main limitations of conventional techniques. Furthermore, in addition to confirming the abnormalities detected by conventional techniques, OGM found new alterations beyond their detection limits.

16 July 2025 in European Journal of Haematology
Verified
Journal Article
Closed access
JIJune Iriondo
June Iriondo
JZJosune Zubicaray
Josune Zubicaray
PRPaula Río
Paula Río
ACAlbert Català
Albert Català
MSMaría Solsona
María Solsona
JSJulián Sevilla
Julián Sevilla

12 April 2025 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
MVMARTA GONZALEZ VICENT
MARTA GONZALEZ VICENT
APA. Peretó
A. Peretó
JZJ. Zubicaray
J. Zubicaray
BMB. Molina
B. Molina
SVS. Vinagre
S. Vinagre
MDMiguel A. Diaz
Miguel A. Diaz